Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 3/20 | 0.57 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.57 |
| ▸ | PPIA | P62937 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7488374 | 0.91 | SGMS2 (0.49) | CXCR2CXCR1PPIAKMT2AKDM4E | |
| SCHEMBL7514780 | 0.86 | CXCR1 (0.56) | CXCR2CXCR1PPIAKMT2ALMNA | |
| SCHEMBL7492629 | 0.86 | CXCR2 (0.62) | CXCR2CXCR1PPIABRD4TRPM4 | |
| SCHEMBL7551257 | 0.84 | SGMS2 (0.53) | CXCR2CXCR1PPIAKMT2AKDM4E | |
| SCHEMBL3707120 | 0.82 | CXCR1 (0.67) | CXCR2CXCR1KMT2AMAPTKDM4E | |
| SCHEMBL7549892 | 0.80 | KMT2A (0.57) | CXCR2CXCR1PPIAKMT2APKM | |
| SCHEMBL7488381 | 0.77 | SGMS2 (0.46) | PPIAALOX15BRD4 | |
| SCHEMBL7515957 | 0.76 | CXCR2 (0.58) | CXCR2CXCR1PPIAKMT2AKDM4E | |
| SCHEMBL31014109 | 0.74 | PARP10 (0.45) | PPIALMNAMAPTKDM4EALDH1A1 | |
| SCHEMBL7514963 | 0.74 | CXCR2 (0.73) | CXCR2CXCR1KMT2ALMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020128321-A1 | IL-8 receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2002-09-12 | — | — | US | disclosed |
| US-6262113-B1 | HYDROXY- OR MERCAPTO-PHENYLUREAS | SMITHKLINE BEECHAM CORPORATION | 2001-07-17 | — | — | US | disclosed |
| US-6211373-B1 | Phenyl urea antagonists of the IL-8 receptor | SMITHKLINE BEECHAM CORPORATION | 2001-04-03 | — | — | US | disclosed |
| US-5780483-A | IL-8 receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1998-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128321-A1 | IL-8 receptor antagonists | CXCL8, CCR8, IL1RN | CXCR2 15/4885CXCR1 21/4885PPIA 1831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.